drugset / Trial / NCT05869539
ACT-TIL and ANV419 for Advanced Melanoma.
Phase 1
Active not recruiting
10 enrolled
University Hospital, Basel, Switzerland
Anaveon AG · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study we aim to investigate safety and tolerability of tumor-infiltrating lymphocytes (TIL) adoptive cell therapy (ACT) incorporation in-vivo TIL expansion with ANV419 in patients with advanced melanoma
Timeline
- Start
- 2023-06-21
- Primary completion
- 2026-04
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANV419 | Protein / enzyme biologic | 243 ug/kg | Intravenous |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 5e+09 cells | Intravenous |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 2e+11 cells | Intravenous |